Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2015

Open Access 01-12-2015 | Research article

Effect of metabolic control on oxidative stress, subclinical atherosclerosis and peripheral artery disease in diabetic patients

Authors: Ozra Tabatabaei-Malazy, Hossein Fakhrzadeh, Farshad Sharifi, Mojde Mirarefin, Seyed Masoud Arzaghi, Zohre Badamchizadeh, Mahtab Alizadeh Khoee, Bagher Larijani

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2015

Login to get access

Abstract

Introduction

By rising diabetes mellitus prevalence, the prevalence of its most complication; cardiovascular disease (CVD) is also increasing. Moreover, oxidative stress has important role in pathogenesis of diabetes and its complications. We investigated relationship between total antioxidant status (TAS) and surrogate measures of subclinical atherosclerosis (SA) with glycemic status in diabetics.

Methods & materials

In a cross-sectional study, we recorded height, weight, waist circumference (WC) and blood pressure of 267 subjects. Blood samples were collected to measure fasting blood sugar (FBS), glycated hemoglobin (HbA1c), lipid profiles and TAS. The surrogate measures of SA were Carotid Intima Media Thickness (CIMT), and Ankle Brachial Index (ABI).

Results

We found significantly lower TAS leves and ABI values and higher CIMT in diabetic patients especially in poor glycemic group. There was a nonsignificant, weak correlation between TAS, ABI and CIMT with glycemic status (r = −0.10, −0.16, and +0.09, respectively). Multivariate regression analysis showed a significant influence of increasing age and diabetes duration on worsening CIMT in poor glycemic group.

Conclusions

Our study showed poor glycemic control leads to worse CIMT by increasing age and duration of diabetes. However we did not find a significan correlation between glycemic status and TAS levels. We suggest CIMT measurement along with other SA markers in poor glycemic diabetics, especially in older patients with longer duration of diabetes, to identify high risk CVD patients.
Footnotes
1
National Cholesterol Education Program-Adult Treatment Panel III 
 
Literature
1.
go back to reference Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Am Heart Assoc. 2004;24:816–23. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Am Heart Assoc. 2004;24:816–23.
2.
go back to reference Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59:365–73.PubMedCrossRef Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59:365–73.PubMedCrossRef
3.
go back to reference Saeidnia S, Abdollahi M. Toxicological and pharmacological concerns on oxidative stress and related diseases. Toxicol Appl Pharmacol. 2013;273:442–55.PubMedCrossRef Saeidnia S, Abdollahi M. Toxicological and pharmacological concerns on oxidative stress and related diseases. Toxicol Appl Pharmacol. 2013;273:442–55.PubMedCrossRef
4.
go back to reference Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007;116(2):151–7.PubMedCrossRef Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007;116(2):151–7.PubMedCrossRef
5.
go back to reference Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease study. Lancet. 1997;349:1498–504.PubMedCrossRef Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease study. Lancet. 1997;349:1498–504.PubMedCrossRef
6.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef
7.
go back to reference Tabatabaei-Malazy O, Qorbani M, Samavat T, Sharifi F, Larijani B, Fakhrzadeh H. Prevalence of dyslipidemia in Iran: a systematic review and meta-analysis study. Int J Prev Med. 2014;5(4):373–93.PubMedPubMedCentral Tabatabaei-Malazy O, Qorbani M, Samavat T, Sharifi F, Larijani B, Fakhrzadeh H. Prevalence of dyslipidemia in Iran: a systematic review and meta-analysis study. Int J Prev Med. 2014;5(4):373–93.PubMedPubMedCentral
8.
go back to reference Herman WH, Fajans SS. Hemoglobin A1c for the diagnosis of diabetes: practical considerations. Pol Arch Med Wewn. 2010;120(1–2):37–40.PubMed Herman WH, Fajans SS. Hemoglobin A1c for the diagnosis of diabetes: practical considerations. Pol Arch Med Wewn. 2010;120(1–2):37–40.PubMed
9.
go back to reference American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1:S81–90.CrossRef American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1:S81–90.CrossRef
10.
go back to reference Bakhtiari S, Bigom Taheri J, Bakhshi M, Mortazavi H, Shah Hoseini A, Vahid Dastjerdi E, et al. Effect of vitamin C on salivary total antioxidant capacity in smokers. Iran J Pharm Res. 2012;11(4):1045–9.PubMedPubMedCentral Bakhtiari S, Bigom Taheri J, Bakhshi M, Mortazavi H, Shah Hoseini A, Vahid Dastjerdi E, et al. Effect of vitamin C on salivary total antioxidant capacity in smokers. Iran J Pharm Res. 2012;11(4):1045–9.PubMedPubMedCentral
11.
go back to reference Wang Y, Chun OK, Song WO. Plasma and dietary antioxidant status as cardiovascular disease risk factors: a review of human studies. Nutrients. 2013;5(8):2969–3004.PubMedPubMedCentralCrossRef Wang Y, Chun OK, Song WO. Plasma and dietary antioxidant status as cardiovascular disease risk factors: a review of human studies. Nutrients. 2013;5(8):2969–3004.PubMedPubMedCentralCrossRef
13.
go back to reference Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, et al. From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol. 2006;98(2A):2H–15.PubMedCrossRef Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, et al. From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol. 2006;98(2A):2H–15.PubMedCrossRef
14.
go back to reference Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459–67.PubMedCrossRef Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459–67.PubMedCrossRef
15.
go back to reference Dobby AV, Anand SS. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol. 2005;25:1463–9.CrossRef Dobby AV, Anand SS. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol. 2005;25:1463–9.CrossRef
16.
go back to reference Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.PubMedCrossRef Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.PubMedCrossRef
17.
go back to reference Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.PubMedCrossRef Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD,  et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.PubMedCrossRef
18.
go back to reference Friedewalds WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifuge. Clin Chem. 1972;18:499–502.CrossRef Friedewalds WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifuge. Clin Chem. 1972;18:499–502.CrossRef
20.
go back to reference Bogousslavsky J, Melle GV, Regli F. The Lausanne stroke registry. Analysis of 1000 consecutive patients with first stroke. Stroke. 1988;19:1083–92.PubMedCrossRef Bogousslavsky J, Melle GV, Regli F. The Lausanne stroke registry. Analysis of 1000 consecutive patients with first stroke. Stroke. 1988;19:1083–92.PubMedCrossRef
21.
go back to reference O’Donnell CJ, Elosua R. Cardiovascular risk factors. Insights from Framingham Heart Study. Rev Esp Cardiol. 2008;61(3):299–310.PubMedCrossRef O’Donnell CJ, Elosua R. Cardiovascular risk factors. Insights from Framingham Heart Study. Rev Esp Cardiol. 2008;61(3):299–310.PubMedCrossRef
22.
go back to reference Turner RC. The UK, prospective diabetic study: a review. Diabetic Care. 1998;21:C35–8.CrossRef Turner RC. The UK, prospective diabetic study: a review. Diabetic Care. 1998;21:C35–8.CrossRef
23.
go back to reference Manohar SM, Vaikasuvu SR, Deepthi K, Sachan A, Narasimha SR. An association of hyperglycemia with plasma malondialdehyde and atherogenic lipid risk factors in newly diagnosed type 2 diabetic patients. J Res Med Sci. 2013;18(2):89–93.PubMedPubMedCentral Manohar SM, Vaikasuvu SR, Deepthi K, Sachan A, Narasimha SR. An association of hyperglycemia with plasma malondialdehyde and atherogenic lipid risk factors in newly diagnosed type 2 diabetic patients. J Res Med Sci. 2013;18(2):89–93.PubMedPubMedCentral
24.
go back to reference Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE. Effects of vitamins C and E and beta-carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: a randomized controlled trial. Am J Clin Nutr. 2009;90:429–37.PubMedPubMedCentralCrossRef Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE. Effects of vitamins C and E and beta-carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: a randomized controlled trial. Am J Clin Nutr. 2009;90:429–37.PubMedPubMedCentralCrossRef
25.
go back to reference Ahuja A, Roopakala MS, Silvia WD, Sanjay Reddy S, Kumar KMP. Glycated hemoglobin, dyslipidemia and risk of atherosclerosis in type 1 diabetic patients. Int J Diabetes Dev Ctries. 2011;31(1):18–21.CrossRef Ahuja A, Roopakala MS, Silvia WD, Sanjay Reddy S, Kumar KMP. Glycated hemoglobin, dyslipidemia and risk of atherosclerosis in type 1 diabetic patients. Int J Diabetes Dev Ctries. 2011;31(1):18–21.CrossRef
26.
go back to reference Tabatabaei-Malazy O, Nikfar S, Larijani B, Abdollahi M. Influence of ascorbic acid supplementation on type 2 diabetes mellitus in observational and randomized controlled trials; a systematic review with meta-analysis. J Pharm Pharm Sci. 2014;17(4):554–82.PubMedCrossRef Tabatabaei-Malazy O, Nikfar S, Larijani B, Abdollahi M. Influence of ascorbic acid supplementation on type 2 diabetes mellitus in observational and randomized controlled trials; a systematic review with meta-analysis. J Pharm Pharm Sci. 2014;17(4):554–82.PubMedCrossRef
27.
go back to reference Cakatay U. Protein oxidation parameters in type 2 diabetic patients with good and poor glycaemic control. Diabetes Metab. 2005;31(6):551–7.PubMedCrossRef Cakatay U. Protein oxidation parameters in type 2 diabetic patients with good and poor glycaemic control. Diabetes Metab. 2005;31(6):551–7.PubMedCrossRef
29.
go back to reference Moriel P, Plavnik FL, Zanella MT, Bertolami MC, Abdalla DS. Lipid peroxidation and antioxidants in hyperlipidemia and hypertension. Biol Res. 2000;33(2):105–12.PubMedCrossRef Moriel P, Plavnik FL, Zanella MT, Bertolami MC, Abdalla DS. Lipid peroxidation and antioxidants in hyperlipidemia and hypertension. Biol Res. 2000;33(2):105–12.PubMedCrossRef
30.
go back to reference García-Fontana B, Morales-Santana S, Longobardo V, Reyes-García R, Rozas-Moreno P, García-Salcedo JA, et al. Relationship between proinflammatory and antioxidant proteins with the severity of cardiovascular disease in type 2 diabetes mellitus. Int J Mol Sci. 2015;16(5):9469–83.PubMedPubMedCentralCrossRef García-Fontana B, Morales-Santana S, Longobardo V, Reyes-García R, Rozas-Moreno P, García-Salcedo JA, et al. Relationship between proinflammatory and antioxidant proteins with the severity of cardiovascular disease in type 2 diabetes mellitus. Int J Mol Sci. 2015;16(5):9469–83.PubMedPubMedCentralCrossRef
31.
go back to reference Steiner G. Lipid intervention trials in diabetes. Diabetes Care. 2000;23 Suppl 2:B49–53.PubMed Steiner G. Lipid intervention trials in diabetes. Diabetes Care. 2000;23 Suppl 2:B49–53.PubMed
33.
go back to reference Weber LA, Cheezum MK, Reese JM, Lane AB, Haley RD, Lutz MW, et al. Cardiovascular imaging for the primary prevention of atherosclerotic cardiovascular disease events. Curr Cardiovasc Imaging Rep. 2015;8(9):36. PubMed.PubMedPubMedCentralCrossRef Weber LA, Cheezum MK, Reese JM, Lane AB, Haley RD, Lutz MW, et al. Cardiovascular imaging for the primary prevention of atherosclerotic cardiovascular disease events. Curr Cardiovasc Imaging Rep. 2015;8(9):36. PubMed.PubMedPubMedCentralCrossRef
34.
go back to reference Hunt KJ, Williams K, Rivera D, O'Leary DH, Haffner SM, Stern MP, et al. Elevated carotid artery intima media thickness levels in individuals who subsequently develop type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003;23(10):1845–50.PubMedCrossRef Hunt KJ, Williams K, Rivera D, O'Leary DH, Haffner SM, Stern MP,  et al. Elevated carotid artery intima media thickness levels in individuals who subsequently develop type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003;23(10):1845–50.PubMedCrossRef
35.
go back to reference Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, et al. Intensive diabetes therapy and carotid intimamedia thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294–303.PubMedCrossRef Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, et al. Intensive diabetes therapy and carotid intimamedia thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294–303.PubMedCrossRef
38.
go back to reference Rashid SA, Mahmud SA. Correlation between carotid artery intima-media thickness and luminal diameter with body mass index and other cardiovascular risk factors in adults. Sultan Qaboos Univ Med J. 2015;15(3):e344–50. 10.18295/squmj.2015.15.03.007.PubMedPubMedCentralCrossRef Rashid SA, Mahmud SA. Correlation between carotid artery intima-media thickness and luminal diameter with body mass index and other cardiovascular risk factors in adults. Sultan Qaboos Univ Med J. 2015;15(3):e344–50. 10.18295/squmj.2015.15.03.007.PubMedPubMedCentralCrossRef
39.
go back to reference Nagasawa SY, Ohkubo T, Masaki K, Barinas-Mitchell E, Miura K, Seto T, et al. Associations between inflammatory markers and subclinical atherosclerosis in middle-aged white, Japanese-American and Japanese men: the ERA-JUMP Study. J Atheroscler Thromb. 2015;22(6):590–8. doi:https://doi.org/10.5551/jat.23580.PubMedCrossRef Nagasawa SY, Ohkubo T, Masaki K, Barinas-Mitchell E, Miura K, Seto T, et al. Associations between inflammatory markers and subclinical atherosclerosis in middle-aged white, Japanese-American and Japanese men: the ERA-JUMP Study. J Atheroscler Thromb. 2015;22(6):590–8. doi:https://​doi.​org/​10.​5551/​jat.​23580.PubMedCrossRef
41.
go back to reference Fakhrzadeh H, Alatab S, Sharifi F, Mirarefein M, Badamchizadeh Z, Ghaderpanahi M, et al. Carotid intima media thickness, brachial flow mediated dilation and previous history of gestational diabetes mellitus. J Obstet Gynaecol Res. 2012;38(8):1057–63.PubMedCrossRef Fakhrzadeh H, Alatab S, Sharifi F, Mirarefein M, Badamchizadeh Z, Ghaderpanahi M, et al. Carotid intima media thickness, brachial flow mediated dilation and previous history of gestational diabetes mellitus. J Obstet Gynaecol Res. 2012;38(8):1057–63.PubMedCrossRef
42.
go back to reference Koskinen J, Kahonen M, Viikari JSA, Taittonen L, Laitinen T, Ronnemaa T, et al. Conventional cardiovascular risk factors and metabolic syndrome in predicting carotid intima-media thickness progression in young adults: the cardiovascular risk in young Finns study. Circulation. 2009;120:229–36.PubMedCrossRef Koskinen J, Kahonen M, Viikari JSA, Taittonen L, Laitinen T, Ronnemaa T, et al. Conventional cardiovascular risk factors and metabolic syndrome in predicting carotid intima-media thickness progression in young adults: the cardiovascular risk in young Finns study. Circulation. 2009;120:229–36.PubMedCrossRef
44.
go back to reference Bianchi C, Penno G, Pancani F, Civitelli A, Piaggesi A, Caricato F, et al. Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;2:246–53.CrossRef Bianchi C, Penno G, Pancani F, Civitelli A, Piaggesi A, Caricato F, et al. Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;2:246–53.CrossRef
45.
go back to reference Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes-a review. Diabet Med. 2010;27(1):4–14.PubMedCrossRef Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes-a review. Diabet Med. 2010;27(1):4–14.PubMedCrossRef
47.
go back to reference Muntner P, Wildman RP, Reynolds K, Desalvo KB, Chen J, Fonseca V. Relationship between HbA1c level and peripheral arterial disease. Diabetes Care. 2005;28:1981–7.PubMedCrossRef Muntner P, Wildman RP, Reynolds K, Desalvo KB, Chen J, Fonseca V. Relationship between HbA1c level and peripheral arterial disease. Diabetes Care. 2005;28:1981–7.PubMedCrossRef
48.
go back to reference Behzad M, Negah R, Sureer B, Neda R. A review of thiazolidine diones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc Health Risk Manag. 2007;3:967–73.PubMedCentral Behzad M, Negah R, Sureer B, Neda R. A review of thiazolidine diones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc Health Risk Manag. 2007;3:967–73.PubMedCentral
49.
go back to reference Li W, Chen Y, Li S, Guo X, Zhou W, Zeng Q, et al. Agonistic antibody to angiotensin II type 1 receptor accelerates atherosclerosis in ApoE−/− mice. Am J Transl Res. 2014;6(6):678–90.PubMedPubMedCentral Li W, Chen Y, Li S, Guo X, Zhou W, Zeng Q, et al. Agonistic antibody to angiotensin II type 1 receptor accelerates atherosclerosis in ApoE−/− mice. Am J Transl Res. 2014;6(6):678–90.PubMedPubMedCentral
50.
go back to reference Lim S, Barter P. Antioxidant effects of statins in the management of cardiometabolic disorders. J Atheroscler Thromb. 2014;21(10):997–1010.PubMedCrossRef Lim S, Barter P. Antioxidant effects of statins in the management of cardiometabolic disorders. J Atheroscler Thromb. 2014;21(10):997–1010.PubMedCrossRef
Metadata
Title
Effect of metabolic control on oxidative stress, subclinical atherosclerosis and peripheral artery disease in diabetic patients
Authors
Ozra Tabatabaei-Malazy
Hossein Fakhrzadeh
Farshad Sharifi
Mojde Mirarefin
Seyed Masoud Arzaghi
Zohre Badamchizadeh
Mahtab Alizadeh Khoee
Bagher Larijani
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2015
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/s40200-015-0215-5

Other articles of this Issue 1/2015

Journal of Diabetes & Metabolic Disorders 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.